Hims & Hers Health

JPMorgan initiated coverage of Hims & Hers with a neutral rating and a $32 price target for December 2027. The bank praises the rapid direct‑to‑consumer growth but sees execution risks in the strategic pivot to approved branded GLP‑1 drugs rather than compounded formulations. Hims & Hers, in partnership with Novo Nordisk, fulfilled more than 125,000 Wegovy shipments in the first six weeks; JPMorgan forecasts $1.1bn in GLP‑1 revenue for 2026 and sees long‑term potential through 2030, but requires proof of successful execution, sustainable growth in new specialty areas, and margin expansion. » Więcej na de.investing.com

Hims & Hers is introducing its brand in Australia by renaming the acquired men’s health platform Pilot to Hims. Existing Pilot patients will retain their treatment plans and providers; the offering includes sexual health, weight-loss and hair-loss treatments. The company has expanded customer support to 24/7, introduced new treatment combinations and clinical pathways, and is reorganizing leadership for the market. Hims & Hers acquired Eucalyptus in early 2026; the announcement notes integration, competitive and retention risks. » Więcej na de.investing.com

Visa enrolled Hims & Hers in its Acquirer Monitoring Program after dispute rates for the company’s weight-loss subscriptions exceeded Visa’s 1.5% threshold. Hims faces an ~$75,000 surcharge in September and must keep disputes below 1.5% for three consecutive months to exit the program. The action compounds regulatory pressure from a recent FTC lawsuit over billing and cancellation practices, though Hims says disputed charges are a small number and is taking corrective steps. Shares tumbled after the news despite strong subscriber growth and rising revenue alongside widening losses and margin pressure. » Więcej na finance.yahoo.com

Hims & Hers was placed in Visa's Acquirer Monitoring Program after the number of credit card complaints in its subscription business for weight-loss products exceeded allowable thresholds in July. Each complaint carries an $8 penalty fee, which, according to internal documents, could result in a bill of nearly $75,000 due in September. Visa is demanding that the complaint rate be reduced to under 1.5% of transactions for three consecutive months; Hims & Hers says the number of disputed charges is relatively small and that it has implemented measures to improve the checkout process. » Więcej na de.investing.com

Chief legal officer Soleil Boughton reported a non‑discretionary sale of 21,500 Hims & Hers Health shares on August 14 to satisfy tax withholding tied to vested restricted stock units, raising about $605,000 at $28.15 per share. Boughton retains 339,075 directly held shares and additional vested and unvested awards. The company faces a recent FTC lawsuit (a $47.5 million legal contingency) even as revenue grew 38% last quarter and management raised full‑year guidance, while the stock is down about 40% over the past year. » Więcej na finance.yahoo.com